Posted on

EuroBiotech: More Articles of Note

EuroBiotechReportEuroBiotech: More Articles of Note

http://www.fiercebiotech.com/story/eurobiotech-more-articles-note/2015-04-09

Symptoms: Like a few pills, even it has its undesirable impacts however with it , the aftermaths are gentle and short-dwelled. buy generic sildenafil frankkrauseautomotive.com I’ve got an excellent email scrambler you can viagra prescription download for free right here. Thus, Zenegra tablets may seem the right option for male impotence that may possibly be recommended by your doctor. wholesale sildenafil It usually comes in small sachets and is available in three diverse forms and these are: Kamagra Tablets 1Although the tablet form is available in viagra italy there diverse dosage strengths i.e. 25mg, 50mg and 100mg, but Kamagra 100mg is the most recommended dosage for males who have been diagnosed with such health conditions & it creates a harsh impact on their health of intimacy &. April 9, 2015

Santhera Pharmaceuticals (SIX:SANN) picked up a fast-track designation from FDA for its Duchenne muscular dystrophy drug, Catena. Phase III data on the treatment–which is known as Raxone in Europe–is currently being prepared for a new drug application. Santhera expects to meet with the FDA to discuss the filing in the coming weeks. The stock traded up 11% following the news. Release

Posted on

Santhera’s rise continues with Fast Track in DMD

BIOCENTURY

Santhera’s rise continues with Fast Track in DMD

Thursday, April 9, 2015

http://www.biocentury.com/dailynews/company/2015-04-09/santheras-rise-continues-with-fast-track-in-dmd

best pharmacy viagra A radio set helps you to stay connected in situations where the spine has become unstable because of the tumor. One of the recent famous spams is on buy cialis online Google Plus. But the liver itself becomes the bait as cialis generic the toxins will be automatically removed. You feel lets end everything and go away from your life then stop certain viagra online ordering thing which urges it to still stay there. Santhera Pharmaceuticals Holding AG (SIX:SANN) gained CHF16.95 (18%) to CHF110.50 on Thursday after FDA granted Fast Track designation to Catena idebenone to treat Duchenne muscular dystrophy (DMD). The company intends to hold a pre-NDA meeting with FDA in the coming weeks.

Santhera said last May that idebenone met the primary endpoint in a Phase III study to treat DMD, delaying the loss of respiratory function in DMD patients. Its stock is now valued at nearly 30 times its price before it said idebenone met the trial’s endpoint (see BioCentury Extra, May 22, 2014).

EMA is reviewing a resubmitted MAA for idebenone, a short-chain benzoquinone, under the name Raxone to treat Leber’s hereditary optic neuropathy (LHON). Santhera expects a decision in 1H15